An inosine 5′-monophosphate dehydrogenase 2 single-nucleotide polymorphism impairs the effect of mycophenolic acid

Pharmacogenomics Journal

Volumn 10, Issue 1, 2010, Pages 70-76

  Winnicki, W ^a   Weigel, G ^a   Sunder Plassmann, G ^a   Bajari, T ^a   Winter, B ^a   Herkner, H ^a   Sengoelge, G ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

IMPDH2; Inosine 50 monophosphate dehydrogenase activity; Lymphocyte proliferation; Mycophenolic acid; SNP

Indexed keywords

GENOMIC DNA; INOSINATE DEHYDROGENASE; MYCOPHENOLIC ACID; IMMUNOSUPPRESSIVE AGENT; IMPDH2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA PROBE; DNA SEQUENCE; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; EXON; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INTRON; LYMPHOCYTE PROLIFERATION; MALE; NORMAL HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE; CELL PROLIFERATION; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; LYMPHOCYTE;

CELL PROLIFERATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; LYMPHOCYTES; MYCOPHENOLIC ACID; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 75549084491     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2009.43     Document Type: Article

References (21)

1. Zimmermann AG, Gu JJ, Laliberte J, Mitchell BS. Inosine-5'-monophosphate dehydrogenase: regulation of expression and role in cellular proliferation and T lymphocyte activation. Prog Nucleic Acid Res Mol Biol 1998; 61: 181-209.
2. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus 2005; 14(Suppl 1): 2-8.
3. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005; 80(Suppl 2): 181-190.
4. Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993; 268: 27286-27290.
5. Wang J, Zeevi A, Webber S, Girnita DM, Addonizio L, Selby R et al. A novel variant L263F in human inosine 5'-monophosphate dehydro-genase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics 2007; 17: 283-290.
6. Quiroz Y, Herrera-Acosta J, Johnson RJ, Rodriguez-Iturbe B. Myco-phenolate mofetil treatment in conditions different from organ transplantation. Transplant Proc 2002; 34: 2523-2526.
7. Salvadori M, Holzer H, de Mattos A, Sollinger H, Arns W, Oppenheimer F et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231-236. (Pubitemid 38248526)
8. Sadek S, Medina J, Arias M, Sennesael J, Squifflet JP, Vogt B. Short-term combination of mycophenolate mofetil with cyclosporine as a therapeutic option for renal transplant recipients: a prospective, multicenter, randomized study. Transplantation 2002; 74: 511-517.
9. Glander P, Hambach P, Braun KP, Fritsche L, Giessing M, Mai I et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004; 4: 2045-2051.
10. Arns W, Cibrik DM, Walker RG, Mourad G, Budde K, Mueller EA et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplantation 2006; 82: 1004-1012.
11. Devyatko E, Dunkler D, Bohdjalian A, Zuckermann A, Grimm M, Muehlbacher F et al. Lymphocyte activation and correlation with IMPDH activity under therapy with mycophenolate mofetil. Clin Chim Acta 2008; 394: 67-71.
12. Glander P, Braun KP, Hambach P, Bauer S, Mai I, Roots I et al. Non-radioactive determination of inosine 5'-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin Biochem 2001; 34: 543-549.
13. Kobashigawa JA, Renlund DG, Gerosa G, Almenar L, Eisen HJ, Keogh AM et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant 2006; 25: 935-941.
14. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007; 46: 13-58.
15. Satoh S, Tada H, Murakami M, Tsuchiya N, Li Z, Numakura K et al. Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. Transplantation 2006; 82: 486-493.
16. van Gelder T, Silva HT, de Fijter JW, Budde K, Kuypers D, Tyden G et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 2008; 86: 1043-1051.
17. Zheng HX, Zeevi A, McCurry K, Schuetz E, Webber S, Ristich J et al. The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. Transpl Immunol 2005; 14: 37-42.
18. MacPhee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A et al. The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. Am J Transplant 2004; 4: 914-919.
19. Zhu G, Vestbo J, Lenney W, Silverman M, Whyte M, Helms P et al. Association of PTGDR gene polymorphisms with asthma in two Caucasian populations. Genes Immun 2007; 8: 398-403.
20. Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006; 8: R182.
21. Grinyo J, Vanrenterghem Y, Nashan B, Vincenti F, Ekberg H, Lindpaintner K et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int 2008; 21: 879-891.